Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Pomalidomide in Indian Healthy Volunteers
NCT06058689Phase 1Not yet recruiting
- Sponsor
- Megalabs
- Start
- Sep 2024
- Primary completion
- Nov 2024
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Megalabs. Primary endpoints: Maximum Plasma Concentration at Day 10, Area Under the Curve from time zero to last measurable concentration at Day 10 and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06058689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058689.